TDMMF (Mach7 Technologies) 3-Year RORE % : 20.69% (As of Dec. 2025)


TDMMF Mach7 Technologies Ltd TDMMF
32 GF Score
Price $0.21
GF Value $0.65
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mach7 Technologies 3-Year RORE %?

Mach7 Technologies TDMMF -10.12% 32 3-Year RORE % is 20.69 as of Dec. 2025. GuruFocus rates TDMMF with a GF Score™ of 32/100 and a GF Value™ of $0.65 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 605 Healthcare Providers & Services companies, Mach7 Technologies ranks better than 72.4% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Mach7 Technologies's 3-Year RORE % for the quarter that ended in Dec. 2025 was 20.69%.

The industry rank for Mach7 Technologies's 3-Year RORE % or its related term are showing as below:

TDMMF's 3-Year RORE % is ranked better than
72.4% of 605 companies
in the Healthcare Providers & Services industry
Industry Median: 0.07 vs TDMMF: 20.69

Mach7 Technologies  (OTCPK:TDMMF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Mach7 Technologies 3-Year RORE % Related Terms


Mach7 Technologies 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Mach7 Technologies's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mach7 Technologies 3-Year RORE % Chart

Mach7 Technologies Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.81 31.71 -60.00 27.03 33.33

Mach7 Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.86 27.03 7.32 33.33 20.69

TDMMF vs VEEV, BTSG, TEM: 3-Year RORE % Comparison

For the Health Information Services subindustry, Mach7 Technologies's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mach7 Technologies 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mach7 Technologies's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Mach7 Technologies's 3-Year RORE % falls into.


TDMMF
32GF Score
Mach7 Technologies Ltd TDMMF
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mach7 Technologies 3-Year RORE % Calculation

Mach7 Technologies's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.028--0.016 )/( -0.058-0 )
=-0.012/-0.058
=20.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 20.69 mean?
Mach7 Technologies (TDMMF) has a 3-Year RORE % of 20.69 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Mach7 Technologies and its competitors. According to the industry distribution chart, Mach7 Technologies ranks #167 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 27.6%.
Is Mach7 Technologies' 3-Year RORE % too high?
Mach7 Technologies' current 3-Year RORE % is 20.69. The Healthcare Providers & Services industry median 3-Year RORE % is 0.07. Mach7 Technologies' value of 20.69 is 29457.1% above this industry median. Based on the distribution chart, Mach7 Technologies ranks #167 out of 605 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Mach7 Technologies has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mach7 Technologies' 3-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Mach7 Technologies ranks #167 out of 605 companies for 3-Year RORE %. This puts Mach7 Technologies in the upper half of its industry. The industry median 3-Year RORE % is 0.07. Mach7 Technologies' value of 20.69 is 29457.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.07, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mach7 Technologies's current 3-Year RORE % of 20.69 is 29457.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Mach7 Technologies and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mach7 Technologies's current 3-Year RORE % is 20.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mach7 Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mach7 Technologies (TDMMF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.65, compared to a current price of $0.21 — trading 67.2% below its estimated fair value. The current 3-Year RORE % is 20.69 and 29457.1% above the Healthcare Providers & Services industry median of 0.07. Mach7 Technologies' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Mach7 Technologies (TDMMF), the current 3-Year RORE % is 20.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mach7 Technologies (TDMMF) Overvalued in 2026?

Based on GuruFocus' analysis, Mach7 Technologies stock appears to be undervalued. The current stock price of $0.21 is trading 67.2% below its estimated GF Value™ of $0.65. GuruFocus considers Mach7 Technologies to be Possible Value Trap.

Key valuation signals for TDMMF:

  • 3-Year RORE %: 20.69
  • GF Value™: $0.65 vs. price of $0.21 (67.2% below fair value)
  • GF Score™: 32/100 with 3 warning signs
  • Industry Position: 29457.1% above the Healthcare Providers & Services median (#167 of 605)

No single metric tells the full story. See the TDMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mach7 Technologies Business Description

Other Exchanges M7T:Australia
Address 120 Kimball Avenue, Suite 210, South Burlington, VT, USA, 05403
Mach7 Technologies Ltd is a healthcare software company focused on enterprise imaging infrastructure. The company's vendor neutral platform enables health systems to manage, access, and exchange medical imaging data across departments, sites, and vendors. It serves across North America, Asia-Pacific, and the Middle East, with deployments ranging from academic medical centres to multi-site health networks. A substantial part of revenue is derived in the form of Subscription revenue. Geographically, it derives a majority of its revenue from North America.
32GF Score

Get the complete analysis for TDMMF

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price
$0.65
GF Value